BioCentury
ARTICLE | Product Development

Revlimid follows Thalomid

May 3, 2004 7:00 AM UTC

Celgene Corp. has halted two Phase III trials of its Revlimid thalidomide analog as a monotherapy in metastatic melanoma after a Data Monitoring Committee (DMC) said they wouldn't show a significant treatment effect. But CELG believes that a combination regimen will work based on data from investigator-led studies of its Thalomid thalidomide plus Temodar temozolamide.

According to spokesperson Brian Gill, the roadmap for Revlimid has been guided by Thalomid. "Wherever Thalomid works, there is a high probability that Revlimid will work," he said...